

Catalog # 10-2146 Irinotecan HCI

(S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'-bipiperidine]-1'-carboxylate hydrochloride

CAS# 100286-90-6

Lot # X102114

Irinotecan is a semi-synthetic derivative of camptothecin that is an FDA approved anticancer drug. It is a prodrug that is converted by tissue esterases to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I.^{1,2} Although irinotecan is also a topoisomerase inhibitor, SN-38 is approximately 1000 times as potent in purified enzyme studies. *In vitro* cytotoxicity assays show much greater variability in potency between the two (2-2000 fold).³

- 1) Kunimoto et al., (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin against murine tumors; Cancer Res. **47** 5944
- 2) Mathijssen et al., (2002) *Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and toptecan;* Curr.Cancer Drug Targets **253** 5892
- 3) Pfizer drug insert

PHYSICAL DATA

Molecular Weight: 623.14

Molecular Formula: C₃₃H₃₈N₄O₆·HCl Purity: >98% by TLC

NMR: (Conforms)

Solubility: DMSO (at least 50 mg/ml); ethanol (up to 4 mg/mL); water (up to 4 mg/mL)

Physical Description: Yellow solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO, ethanol or water may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.